Refractory Chronic Cough

In a trial evaluating a refractory chronic cough treatment, continuous cough monitoring allowed researchers access to an abundance of data and the treatment’s impact over time, according to a presentation at the Hyfe Cough Science Forum.

The FDA has issued a complete response letter declining to approve a new drug application for gefapixant as a treatment for adults with refractory or unexplained chronic cough, according to a press release from Merck.

In November, all but one of the members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee voted against recommending the approval of gefapixant for adults with refractory or unexplained chronic cough.

The Healio Editors compiled the most-read news in pulmonology posted in January.

Lidocaine, delivered as a throat spray to the pharynx, reduced cough frequency in adults with refractory chronic cough, according to data published in the Journal of Allergy and Clinical Immunology: In Practice.

This week, a monoclonal antibody cocktail cut COVID-19 hospitalization and death; removing race correction in lung function tests shows more severe disease in Black patients; gefapixant reduces chronic cough frequency in a large pooled analysis; and more.

Endogenous inhibitor control mechanisms, particularly those active through pain, may reduce coughing and urge to cough, researchers reported in the European Respiratory Journal.

The Healio editors have compiled a list of the most-read pulmonology news from the recent virtual European Respiratory Society International Congress.

Treatment with gefapixant, a P2X3 receptor antagonist reduced cough frequency and cough-related quality of life in patients with refractory or unexplained chronic cough, according to results of two phase 3 trials.

A novel P2X3 receptor antagonist, in multiple doses up to 750 mg, was well tolerated, and higher doses significantly reduced cough count and severity compared with placebo in patients with refractory chronic cough.